Drugs@FDA document
DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE Letter · NDA 215187 ORIG-1
Drugs@FDA document · LUPIN PHARMS · Jul 19, 2023
Key facts
| Drug name | DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE |
|---|---|
| Document type | Letter |
| Application | NDA215187 |
| Submission | ORIG-1 |
| Company | LUPIN PHARMS |
| Document date | Jul 19, 2023 |
| FDA document | accessdata.fda.gov |
At a glance
- 1–9 Documents for this application
- None USP chapters cited in this application's documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: